ADME optimization and toxicity assessment in early- and late-phase drug discovery

Current Topics in Medicinal Chemistry

Volumn 9, Issue 11, 2009, Pages 965-980

  Caldwell, Gary W ^a   Yan, Zhengyin ^a   Tang, Weimin ^a   Dasgupta, Malini ^a   Hasting, Becki ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; REACTIVE OXYGEN METABOLITE; CARCINOGEN; MUTAGENIC AGENT;

CARCINOGEN TESTING; CARDIOTOXICITY; COMPUTER MODEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DNA BINDING; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SOLUBILITY; DRUG STABILITY; ENZYME INHIBITION; HUMAN; LIVER TOXICITY; MUTAGEN TESTING; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; STRUCTURE ACTIVITY RELATION; THERMOSTABILITY; TOXICITY TESTING; DRUG DEVELOPMENT; PERMEABILITY; PHARMACOKINETICS; SOLUBILITY;

CARCINOGENS; DRUG DISCOVERY; MUTAGENS; PERMEABILITY; PHARMACOKINETICS; REACTIVE OXYGEN SPECIES; SOLUBILITY;

EID: 74049143211     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609789630929     Document Type: Review

References (231)

1. Prentis, R. A.; Walker, S. R Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br. J. Clin. Pharmacol. 1988, 25, 387-396.
2. DiMasi, J. A. Risks, regulation, and rewards in new drug development in the United States. Reg. Tox. Pharmacol. 1994, 19, 228-235.
3. DiMasi, J.A. Success rates for new drugs entering clinical testing in the United States. Clin. Pharmacol. Ther. 1995, 58, 1-14.
4. Kennedy, T. Managing the drug discovery/development interface. Drug Discov. Today 1997, 2, 436-444.
5. Dimasi, J. A. New drug development in the United States from 1963 to 1999. Clin. Pharmacol. Ther. 2001, 69(5), 286-96.
6. DiMasi, J. A.; Hansen R. W. Grabowski H. G. The price of innovation: new estimates of drug development costs. J. Health econ. 2003, 22(2), 151-85.
7. Heykants J.; Meuldermans, W. Nonclinical kinetics and metabolism studies in support of the safety assessment of drugs. Drug Inf. J. 1994, 28, 163-172.
8. Rodrigues, A.D. Use of in vitro human metabolism studies in drug development. An industrial Perspective. Biochem. Pharmacol. 1994, 48(12), 2147-56.
9. Welling, P. G. Changing status of pharmacokinetics in drug discovery and development. Int. J. Pharm. Adv. 1995, 1(2), 121-33.
10. Ball, S.E.; Scatina J.A. Sisenwine, S.F., Fisher, G.L.: The application of in vitro models of drug metabolism and toxicity in drug discovery and drug development. Drug Chem. Toxicol. 1995, 18(1) 1-28.
11. Caldwell, J. The role of drug metabolism in drug discovery and development: Opportunities to enhance time- and cost-efficiency. Pharm. Sci. 1996, 2, 117-119.
12. Humphrey, M. J. Application of metabolism and pharmacokinetics studies to the drug discovery process. Drug Metab. Rev. 1996, 28(3), 473-489.
13. Cashman, J. R. Drug discovery and drug metabolism. Drug Discov. Today 1996, 1(5), 209-216.
14. Caldwell, J. The importance of drug metabolism studies for efficient drug discovery and development. Yakubutsu Dotai 1996, 11(1), 119-26
15. Rodrigues, A. D. Preclinical drug metabolism in the age of high-throughput screening: an industrial perspective. Pharm. Res. 1997, 14(11), 1504-1510.
16. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting. Adv. Drug Del. Rev. 1997, 23, 3-25.
17. Grass, G. M. Simulation models to predict oral drug absorption from in vitro data. Adv. Drug Del. Rev. 1997, 23(1-3), 199-219.
18. Rodrigues, A.D. Rational high-throughput screening in preclinical drug metabolism. Med. Chem. Res. 1998, 8(7/8), 422-433.
19. Tarit, M.H.; Berman, J. High-throughput approaches for evaluating absorption distribution, metabolism and excretion properties of lead compounds. Curr. Opin. Chem. Biol. 1998, 2, 411-416.
20. Smith, D.A. High throughput drug metabolism. Biomed. Health Res. 1998, 25, 137-143.
21. Curatolo, W. Physical chemical properties of oral drug candidates in the discovery and exploratory development setting. Pharm. Sci. Technol. Today 1998, 1(9), 387-393.
22. Caldwell, G.W.; Masucci, J.A.; Chacon, E. High throughput liquid chromatography-mass spectrometry assessment of the metabolic activity of commercially available hepatocytes from 96-well plates. Comb. Chem. High Throughput Screen. 1999, 2(1), 39-51.
23. Bayliss, M.K.; Frick, L.W. High-throughput pharmacokinetics: cassette dosing. Curr. Opin. Drug Discov. Dev. 1999, 2(1), 20-25.
24. Smith, D.A.; van de Waterbeemd, H. Pharmacokinetics and metabolism in early drug discovery. Cur. Opin. Chem. Biol. 1999, 3, 373-378.
25. Sinko, P.J. Drug selection in early drug development: screening for acceptable pharmacokinetic properties using combined in vitro and computational approaches. Curr. Opin. Drug Discov. Dev. 1999, 2(1), 42-48.
26. Johnson, D.E.; Braeckman, R.A.; Wolfgang, G.H. Practical aspects of assessing toxicokinetics and toxicodynamics. Curr. Opin. Drug Discov. Dev. 1999, 2(1), 49-57.
27. Todd, M.D.; Ulrich, R.G. Emerging technologies for accelerated toxicity evaluation of potential drug candidates. Curr. Opin. Drug Discov. Dev. 1999, 2(1), 58-68.
28. Crespi, C.L. Higher-throughput screening with human cytochromes P450. Curr. Opin. Drug Discov. Dev. 1999, 2(1), 15-19.
29. Caldwell, G.W. Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetics properties utilizing combined physicochemical, in vitro and in vivo screens. Curr. Opin. Drug Discov. 2000, 3, 30-41.
30. Watt, A.P.; Morrison, D.; Evans, D.C. Approaches to higher-through pharmacokinetics (HTPK) in drug discovery. Drug Discov. Today 2000, 5(1), 17-24.
31. Robertson, D.G.; Bulera, S.J. High-throughput toxicology: practical considerations. Curr. Opin. Drug Discov. 2000, 3, 42-47.
32. Bajpai, M., Adkison K.K.: High-through screening for lead optimization: a rational approach. Curr. Opin. Drug Discov. 2000, 3, 63-71.
33. White, R.E. High-through screening in drug metabolism and pharmacokinetics support of drug discovery. Annu. Rev. Pharmacol. Toxicol. 2000, 40, 133-157.
34. Eddershaw, P.J.; Beresford A.P.; Bayliss M.K.. ADME/PK as part of a rational approach to drug discovery. Drug Discov. Today 2000, 5(9), 409-414.
35. Bertrand, M.; Jackson P.; Walther, B. Rapid assessment of drug metabolism in the drug discovery process. Eur. J. Pharm. Sci. 2000, 11, S61-S72.
36. Lakings, D.B. Nonclinical drug development: pharmacology, drug metabolism, and toxicology. New Drug Approv. 2000, 100, 17-54
37. Caldwell, G. W.; Ritchie, D. M.; Masucci, J. A.; Hageman, W.; Yan, Z. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. Curr. Top. Med. Chem. (Hilversum, Netherlands) 2001, 1(5), 353-366.
38. Kerns, E. H.; Di, Li.: Multivariate pharmaceutical profiling for drug discovery. Curr. Top. Med. Chem. (Hilversum, Netherlands) 2002, 2(1), 87-98
39. Kerns, E. H.; Di, Li. Pharmaceutical profiling in drug discovery. Drug Discov. Today 2003, 8(7), 316-323
40. Roberts, S. A. Drug metabolism and pharmacokinetics in drug discovery. Curr. Opin. Drug Discov. Dev. 2003, 6(1), 66-80.
41. Caldwell, G. W.; Yan, Z.; Masucci, J. A.; Hageman, W.; Leo, G.; Ritchie, D.M. Applied pharmacokinetics in drug development: An overview of drug discovery. Pharm. Dev. Regul. 2003, 1(2), 117-132.
42. Muskal, S. M.; Jha, S. K.; Kishore, M. P.; Tyagi, P. A simple and readily integratable approach to toxicity prediction. J. Chem. Inform. Comp. Sci. 2003, 43(5), 1673-1678.
43. Czar, Michael J. In vitro toxicogenomics to predict in vivo pathology. New Drugs 2003, (2), 20, 22-23.
44. Kerns, E. H.; Di, Li; Petusky, S.; Farris, M.; Ley, R.; Jupp, P. Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. J. Pharm. Sci. 2004, 93(6), 1440-1453.
45. Thompson, T. N. Drug metabolism in vitro and in vivo results: how do these data support drug discovery? Using Mass Spectrometry for Drug Metabolism Studies, CRC Press: Boca Raton, FL, 2005, 35-81.
46. Gomez-Orellana, I. Strategies to improve oral drug bioavailability. Expert Opin. Drug Del. 2005, 2(3), 419-433.
47. Raub, T. J. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol. Pharm. 2006, 3(1), 3-25.
48. Caldwell, G. W.; Yan, Z. Screening for reactive intermediates and toxicity assessment in drug discovery. Curr. Opin. Drug Discov. Dev. 2006, 9(1), 47-60.
49. Wunberg, T.; Hendrix, M.; Hillisch, A.; Lobell, M.; Meier, H.; Schmeck, C.; Wild, H.; Hinzen, B. Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. Drug Discov. Today 2006, 11(3 & 4), 175-180.
50. Thomas, V. H.; Bhattachar, S.; Hitchingham, L.; Zocharski, P.; Naath, M.; Surendran, N.; Stoner, C. L.; El-Kattan, A. The road map to oral bioavailability: an industrial perspective. Expert Opin. Drug Metabol. Toxicol. 2006, 2(4), 591-608.
51. Neervannan, S. Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin. Drug Metab. Toxicol. 2006, 2(5), 715-731.
52. Subramanian, G.; Mjalli, A. M. M.; Kutz, M. E.: Integrated approaches to perform in silico drug discovery. Curr. Drug Discov. Technol. 2006, 3(3), 189-197.
53. Komura, H.; Iwaki, M. Pitfalls in high throughput screening for drug absorption optimization in drug discovery. Curr. Analytical Chem. 2007, 3(4), 302-309.
54. Thakker, D. R. Strategic use of preclinical pharmacokinetic studies and in vitro models in optimizing ADME properties of lead compounds. Biotechnol. Pharm. Aspects 2006, 4(Optimizing the "Drug-Like" Properties of Leads in Drug Discovery), 1-23.
55. Fortuna, A.; Alves, G.; Falcao, A. The importance of permeability screening in drugs discovery process: PAMPA, Caco-2 and rat everted gut assays. Curr. Top. Pharmacol. 2007, 11(2), 63-86.
56. Schoonen, W.G. E. J.; Westerink, W. M. A.; Horbach, G. J. High-throughput screening for analysis of in vitro toxicity. EXS 2009, 99(Molecular, Clinical and Environmental Toxicology, Volume 1), 401-452.
57. Yeon, J. H.; Park, J-K. Drug permeability assay using microhole-trapped cells in a microfluidic device. Analytical Chemistry (Washington, DC, United States) 2009, 81(5), 1944-1951.
58. Di, L.; Kerns, E. H.; Carter, G. T. Drug-like property concepts in pharmaceutical design. Curr. Pharm. Des. 2009, 15(19), 2184-2194.
59. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 2004, 3(8)711-715.
60. Kopec, K. K.; Bozyczko-Coyne, D.; Williams, M. Target identification and validation in drug discovery: the role of proteomics. Biochem. Pharmacol. 2005, 69(8), 1133-1139.
61. Chen, K-J.; Lee, J-C. Establishment of high throughput screening (HTS) for drug discovery. Huaxue 2008, 66(4), 269-277.
62. Janzen, W. P.; Popa-Burke, I. G.: Advances in improving the quality and flexibility of compound management. J. Biomol. Screen. 2009, 14(5) 444-451.
63. Colmenarejo, G. In silico ADME prediction: Data sets and models. Curr. Comput-Aided Drug Des. 2005, 1(4), 365-376.
64. Van de W. H. From in vivo to in vitro/in silico ADME: progress and challenges. Expert Opin. Drug Metab. Toxicol. 2005, 1(1), 1-4.
65. Narayanan, R.; Gunturi, S.B. In silico ADME modeling: prediction models for blood-brain barrier permeation using a systematic variable selection method. Bioorg. Med. Chem. 2005, 13(8), 3017-3028.
66. Helma, C. In silico predictive toxicology: The state-of-the-art and strategies to predict human health effects. Curr. Opin. Drug Discov. Dev. 2005, 8(1), 27-31.
67. Subramanian, G.; Mjalli, A. M. M.; Kutz, M. E.: Integrated approaches to perform in silico drug discovery. Curr. Drug Discov. Technol. 2006, 3(3), 189-197.
68. Bidault, Y. A flexible approach for optimising in silico ADME/Tox characterization of lead candidates. Expert Opin. Drug Metab. Toxicol. 2006, 2(1), 157-168.
69. Pang, Y. P. In Silico drug discovery: solving the "target-rich and lead-poor" imbalance using the genome-to- drug -lead paradigm. Clin. Pharm. Ther. 2007, 81(1), 30-34.
70. Singh, B.; Dhake, A. S.; Sethi, D.; Paul, Y. In silico ADME predictions using quantitative structure pharmacokinetic relationships. Part I: fundamental aspects. Pharm. Rev. 2007, 5(29), 93-100.
71. Singh, B.; Parle, M.; Paul, Y.; Khurana, L. In silico ADME predictions using quantitative structure pharmacokinetic relationships. Part II: descriptors. Pharm. Rev. 2007, 5(30), 63-68.
72. Hop, C. E. C. A.; Cole, M. J.; Davidson, R. E.; Duignan, D. B.; Federico, J.; Janiszewski, J. S.; Jenkins, K.; Krueger, S.; Lebowitz, R.; Liston, T. E.; Mitchell, W.; Snyder, M.; Steyn, S. J.; Soglia, J. R.; Taylor, C.; Troutman, M. D.; Umland, J.; West, M.; Whalen, K. M.; Zelesky, V.; Zhao, S. X.: High throughput ADME screening: practical considerations, impact on the portfolio and enabler of in silico ADME models. Curr. Drug Metab. 2008, 9(9), 847-853.
73. Moda, T. L.; Torres, L. G.; Carrara, A. E.; Andricopulo, A.D. PK/DB: database for pharmacokinetic properties and predictive in silico ADME models. Bioinformatics 2008, 24(19), 2270-2271.
74. De Lisle, Robert K.; Diller, D. J. In silico ADME /tox models: progress and challenges. Curr. Comput-Aided Drug Des. 2009, 5(2), 69-70.
75. Lipinski, C. A.: Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov. Today. Technol. 2004, 1(4), 337-341.
76. Lipinski, C.A. Drug solubility in water and dimethylsulfoxide. Methods Princ. Med. Chem. 2008, 37(Molecular Drug Properties), 257-282.
77. Avdeef, A. Drug ionization and physicochemical profiling. Methods Princ. Med. Chem. 2008, 37(Molecular Drug Properties), 55-83.
78. Petrauskas, A. A.; Kolovanov, E. A. ACD/Log P method description. Perspect. Drug Discov. Des. 2000, 19, 99-116.
79. Leo, A. J.; Hoekman, D. Calculating log P(oct) with no missing fragments; the problem of estimating new interaction parameters. Perspect. Drug Discov. Des. 2000, 18, 19-38.
80. Machatha, S. G.; Yalkowsky, S. H. Comparison of the octanol/water partition coefficients calculated by ClogP ACDlogP and KowWin to experimentally determined values. Int. J. Pharm. 2005, 294(1-2), 185-192.
81. Mannhold, R.; Poda, G. I.; Ostermann, C.; Tetko, I.V.: Calculation of molecular lipophilicity: state-of-the-art and comparison of logP methods on more than 96,000 compounds. J. Pharm. Sci. 2009, 98(3), 861-893.
82. Schroeter, T. S.; Schwaighofer, A.; Mika, S.; Ter Laak, A.; Suelzle, D.; Ganzer, U.; Heinrich, N.; Mueller, K.-R.: Estimating the domain of applicability for machine learning QSAR models: a study on aqueous solubility of drug discovery molecules. J. Comput-Aided Mol. Des. 2007, 21(9), 485-498.
83. Johnson, S. R.; Chen, X-Q.; Murphy, D.; Gudmundsson, O. A computational approach to modeling solubility that includes crystal packing, ionization, and intrinsic solubility for use in iterative design. Abstracts of Papers, 235th ACS National Meeting, April 6-10, 2008.
84. Yalkowsky, S. H.; He, Y. Handbook of Aqueous Solubility Data. CRC Press: Boca Raton, 2003.
85. Bains, W.; Gilbert, R.; Sviridenko, L.; Gascon, J-M.; Scoffin, R.; Birchall, K.; Harvey, I.; Caldwell, J. Evolutionary computational methods to predict oral bioavailability QSPRs. Curr. Opin. Drug Discov. Dev. 2002, 5(1), 44-51.
86. Yoshida, F.; Topliss, J G. QSAR model for drug human oral bioavailability. J. Med. Chem. 2000, 43(13), 2575-2585.
87. Van de Waterbeemd, H.: In silico models to predict oral absorption. Compr. Med. Chem II. 2006, 5, 669-697.
88. Linnankoski, J.; Maekelae, J. M.; Ranta, V.-P.; Urtti, A.; Yliperttula, M. Computational prediction of oral drug absorption based on absorption rate constants in humans. J. Med. Chem. 2006, 49(12), 3674-3681.
89. Tetko, I. V.; Oprea, T. I. Early ADME/T predictions: toy or tool? Chemoinformat. Approaches Virtual Screen. 2008, 240-267.
90. Berellini, G.; Springer, C.; Waters, N. J.; Lombardo, F. In Silico Prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set. J. Med. Chem. 2009, 52(14), 4488-4495.
91. Sui, X.; Sun, J.; Wu, X.; Li, H.; Liu, J.; He, Z.: Predicting the volume of distribution of drugs in humans. Curr. Drug Metab. 2008, 9(6), 574-580.
92. Obach, R. S.: Prediction of human volume of distribution using in vivo, in vitro, and in silico approaches. Ann. Rep. Med. Chem. 2007, 42, 469-488.
93. Ghafourian, T.; Barzegar-Jalali, M.; Dastmalchi, S.; Khavari-Khorasani, T.; Hakimiha, N.; Nokhodchi, A. QSPR models for the prediction of apparent volume of distribution. Int. J. Pharm. 2006, 319(1-2), 82-97.
94. Lombardo, F.; Obach, R. S.; DiCapua, F. M.; Bakken, G. A.; Lu, J.; Potter, D.M.; Gao, F.; Miller, M. D.; Zhang, Y. A hybrid mixture discriminant analysis-random forest computational model for the prediction of volume of distribution of drugs in human. J. Med. Chem. 2006, 49(7), 2262-2267.
95. Lewis, D. F. V. Cytochromes P450, Taylor & Francis Inc., Bristol, PA, 1996.
96. Beedham, C. The role of non-P450 enzymes in drug oxidation. Pharm. World Sci. 1997, 19(6), 255-263.
97. Cashman, J. R. Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Curr. Drug Metab. 2000, 1(2), 181-191.
98. Benedetti, M. S.; Tipton, K. F. Monoamine oxidases and related amine oxidases as phase I enzymes in the metabolism of xenobiotics. J. Neural Transm. Suppl. 1998, 52, 149-171.
99. Greene,N.; Judson, P.N.; Langowski, J.J.; Marchant, C.A. Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. SAR QSAR Environ. Res. 1999, 10(2-3), 299-314.
100. Testa, B.; Balmat, A-L.; Long, A.; Judson, P. Predicting drug metabolism - an evaluation of the expert system METEOR. Chem. Biodivers. 2005, 2(7), 872-885.
101. Zheng, M.; Luo, X.; Shen, Q.; Wang, Y.; Du, Y.; Zhu, W.; Jiang, H. Site of metabolism prediction for six biotransformations mediated by cytochromes P450. Bioinformatics 2009, 25(10), 1251-1258.
102. Li, H.; Sun, J.; Fan, X.; Sui, X.; Zhang, L.; Wang, Y.; He, Z. Considerations and recent advances in QSAR models for cytochrome P450-mediated drug metabolism prediction. J. Comput-Aided Mol. Des. 2008, 22(11), 843-855.
103. Cruciani, G.; Vianello, R.; Baroni, M.; Zamora, I. MetaSite, a suite for metabolism prediction in silico. QSAR and molecular modelling in rational design of bioactive molecules, Proceedings of the European Symposium on Structure-Activity Relationships (QSAR) and Molecular Modelling, 15th, Istanbul, Turkey, Sept. 5-10, 2004 (2006), 189-192.
104. Vermeulen, N. P. E. Prediction of drug metabolism: The case of cytochrome P450 2D6. Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 2003, 3(11), 1227-1239.
105. Advanced Chemistry Development, Inc. 110 Yonge Street, 14th floor, Toronto, Ontario, Canada M5C 1T4.
106. Willmann, S.; Lippert, J.; Schmitt, W. From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools. Expert Opin. Drug Metab. Toxicol. 2005, 1(1), 159-168.
107. Jamei, M.; Marciniak, S.; Feng, K.; Barnett, A.; Tucker, G.; Rostami-Hodjegan, A.: The Simcyp Population-based ADME Simulator. Expert Opin. Drug Metab.Toxicol. 2009, 5(2), 211-223.
108. Emoto, C.; Murayama, N.; Rostami-Hodjegan, A.; Yamazaki, H.: Utilization of estimated physicochemical properties as an integrated part of predicting hepatic clearance in the early drug-discovery stage: impact of plasma and microsomal binding. Xenobiotica 2009, 39(3), 227-235.
109. Klopman, G.; Stefan, L.; Saiakhov, R D. New approach to the evaluation of bioavailability of drugs. Abstr. Paper. Am. Chem. Soc. 2000, 220th COMP-033
110. Cruz-Monteagudo, M.; Borges, F.; Cordeiro, M.N.; Cagide Fajin, J. L.; Morell, C.; Ruiz, R.M.; Cañizares-Carmenate, Y.; Dominguez, E.R. Desirability-based methods of multiobjective optimization and ranking for global QSAR studies. Filtering safe and potent drug candidates from combinatorial libraries. J. Comb. Chem. 2008, 10(6), 897-913.
111. Yamashita, F.; Hashida, M. In silico approaches for predicting ADME properties of drugs. Drug Metab. Pharm. 2004, 19(5), 327-338.
112. Huynh, L.; Masereeuw, R.; Friedberg, T.; Ingelman-Sundberg, M.; Manivet, P. In silico platform for xenobiotics ADME-T pharmacological properties modeling and prediction. Part I: beyond the reduction of animal model use. Drug Discov. Today 2009, 14 (7-8), 401-405.
113. Song, M.; Clark, M. Development and Evaluation of an in Silico Model for hERG Binding. J. Chem. Inf. Model. 2006, 46(1), 392-400.
114. Judson, P.N.; Cooke, P.A.; Doerrer, N.G.; Greene, N.; Hanzlik, R.P.; Hardy, C.; Hartmann, A.; Hinchliffe, D.; Holder, J.; Mueller, L.; Steger-Hartmann, T.; Rothfuss, A.; Smith, M.; Thomas, K.; Vessey, J.D.; Zeiger, E.; Towards the creation of an international toxicology information centre. Toxicology 2005, 213(1-2), 117-128.
115. O'Brien SE, De Groot MJ: Greater Than the Sum of Its Parts: Combining Models for Useful ADMET Prediction. J. Med. Chem. 2005, 48(4), 1287-1291.
116. Alelyunas, Yun W.; Liu, Ruifeng; Pelosi-Kilby, Luciana; Shen, Cindy. Application of a dried-DMSO rapid throughput 24-h equilibrium solubility in advancing discovery candidates. Eur. J. Pharm. Sci. 2009, 37(2), 172-182.
117. van de Waterbeemd, H. Physicochemical approaches to drug absorption. Methods Princ. Med. Chem. 2009, 40(Drug Bioavailability), 71-99.
118. Liu, B.; Chang J.; Gordon W. P.; Isbell J.; Zhou Y.; Tuntland T. Snapshot P. A rapid rodent in vivo preclinical screening approach. Drug Discov. Today 2008, 13(7-8), 360-7.
119. He, K.; Qian, M.; Wong, H.; Bai, S. A.; He, B.; Brogdon, B.; Grace, J. E.; Xin, B.; Wu, J.; Ren, S. X.; Zeng, H.; Deng, Y.; Graden, D. M.; Olah, T. V.; Unger, S. E.; Luettgen, J. M.; Knabb, R. M.; Pinto, D. J.; Lam, P. Y. S.; Duan, J.; Wexler, R. R.; Decicco, C. P.; Christ, D. D.; Grossman, S. J. N-in-1 dosing pharmacokinetics in drug discovery: experience, theoretical and practical considerations. J. Pharm. Sci. 2008, 97(7), 2568-2580.
120. Cox, K. A.; White, R. E.; Korfmacher, W. A.: Rapid determination of pharmacokinetic properties of new chemical entities: In vivo approaches. Comb. Chem. High Throughput Screen. 2002, 5(1) 29-37.
121. Yan, Z.; Rafferty, B.; Caldwell, G. W.; Masucci, J. A.: Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses. Eur. J. Drug Metab. Pharm. 2002, 27(4), 281-287.
122. Yan, Z.; Caldwell, G. W. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr. Top. Med. Chem. 2001, 1(5), 403-425.
123. Kerns, E. H.; Di, L.; Carter, G. T. In vitro solubility assays in drug discovery. Curr. Drug Metab. 2008, 9(9), 879-885.
124. Avdeef, A. Absorption and Drug Development: Solubility, Permeability and Charge State, Wiley-Interscience, New York, New York, 2003.
125. Baka, E.; Comer, J.E. A.; Takacs-Novak, K. Study of equilibrium solubility measurement by saturation shake - flask method using hydrochlorothiazide as model compound. J. Pharm. Biomed. Anal. 2008, 46(2), 335-341.
126. Yamashita, T.; Dohta, Y.; Nakamura, T.; Fukami, T. High-speed solubility screening assay using ultra-performance liquid chromatography/mass spectrometry in drug discovery. J. Chromatogr. A 2008, 1182(1), 72-76.
127. Hageman, M. J.: Solubility, solubilization and dissolution in drug delivery during lead optimization. Biotechnol. Pharm. Aspects 2006, 4, 99-130.
128. Bard, B.; Martel, S.; Carrupt, P.-A. High throughput UV method for the estimation of thermodynamic solubility and the determination of the solubility in biorelevant media. Eur. J. Pharm. Sci. 2008, 33(3), 230-240.
129. Zhou, L.; Yang, L.; Tilton, S.; Wang, J. Development of a high throughput equilibrium solubility assay using miniaturized shake - flask method in early drug discovery. J. Pharm. Sci. 2007, 96(11), 3052-3071.
130. Glomme, A.; Maerz, J.; Dressman, J. B. Comparison of a miniaturized shake - flask solubility method with automated potentiometric acid/base titrations and calculated solubilities. J. Pharm. Sci. 2005, 94(1), 1-16.
131. Uchida, M.; Fukazawa, T.; Yamazaki, Y.; Hashimoto, H.; Miyamoto, Y. A modified fast (4 day) 96-well plate Caco - 2 permeability assay. J. Pharm. Toxic. Methods 2009, 59(1), 39-43.
132. Fortuna, A.; Alves, G.; Falcao, A. The importance of permeability screening in drugs discovery process: PAMPA, Caco - 2 and rat everted gut assays. Curr. Top. Pharmacol. 2007, 11(2), 63-86.
133. Thomas, S.; Brightman, F.; Gill, H.; Lee, S.; Pufong, B. Simulation modelling of human intestinal absorption using Caco - 2 permeability and kinetic solubility data for early drug discovery. J. Pharm. Sci. 2008, 97(10), 4557-4574.
134. Go, Woon-Jung; Cheon, Eun-pa; Han, Hyo-Kyung. Comparison of Caco - 2 and MDCK cells as an in vitro ADME screening model. Yakche Hakhoechi 2008, 38(3), 183-189.
135. Sun, H.; Chow, E. C. Y.; Liu, S.; Du, Y.; Pang, K. S. The Caco - 2 cell monolayer: usefulness and limitations. Expert Opin. Drug Metab. Toxicol. 2008, 4(4), 395-411.
136. Avdeef, A.; Bendels, S.; Di, L.; Faller, B.; Kansy, M.; Sugano, K.; Yamauchi, Y. Parallel artificial membrane permeability assay (PAMPA)-critical factors for better predictions of absorption. J. Pharm. Sci. 2007, 96(11), 2893-2909.
137. Caldwell, G. W.; Easlick, S. M.; Gunnet, J.; Masucci, J.A.; Demarest, K. In vitro permeability of eight β -blockers through caco-2 monolayers utilizing liquid chromatography/electrospray ionization mass spectrometry. J. Mass. Spectrom. 1998, 33(7), 607-614.
138. Irvine, J. D.; Takahashi, L; Lockhart, K.; Cheong, J.; Tolan, J. W.; Selick, H. E.; Grove, J. R. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 1999, 88(1) 28-33.
139. Hidalgo, I. J. Assessing the absorption of new pharmaceuticals. Curr. Top. Med. Chem. 2001, 1(5), 385-401.
140. Vanhulle, V. P.; Martiat, G. A.; Verbeeck, R. K.; Horsmans, Y.; Calderon, P. Buc; Eeckhoudt, S. L.; Taper, H. S.; Delzenne, N. Cryopreservation of rat precision-cut liver slices by ultrarapid freezing. Influence on phase I and II metabolism and on cell viability upon incubation for 24 hours. Life Sci. 2001, 68(21), 2391-2403.
141. Ekins, S.; Ring, B. J.; Grace, J.; McRobie-Belle, D. J.; Wrighton, S. A. Present and future in vitro approaches for drug metabolism. J. Pharmacol. Toxicol. Methods 2001, 2000, 44(1), 313-324.
142. Guillouzo, A.; Rialland, L.; Fautrel, A.; Guyomard, C. Survival and function of isolated hepatocytes after cryopreservation. Chem. Biol. Interact. 1999, 121(1), 7-16.
143. Li, A. P. Overview: hepatocytes and cryopreservation-a personal historical perspective. Chem.-Biol. Interact. 1999, 121(1), 1-5.
144. Caldwell G.W.; Masucci J.A.; Chacon, E. High throughput liquid chromatography-mass spectrometry assessment of the metabolic activity of commercially available hepatocytes from 96-well plates. Comb. Chem. High Throughput Screen. 1999, 2(1), 39-51.
145. Umehara, K.; Kudo, S.; Hirao, Y.; Morita, S.; Uchida, M.; Odomi, M.; Miyamoto, G. Oxidative cleavage of the octyl side chain of 1-(3,4- dichlorobenzyl)-5-octylbiguanide (OPB-2045) in rat and dog liver preparations. Drug Metab. Dispos. 2000, 28(8), 887-894.
146. Wu, W.-N.; McKown, L. A. In vitro drug metabolite profiling using hepatic S9 and human liver microsomes. Optim. Drug Discov. 2004, 163-184.
147. Crespi C.L. Higher-throughput screening with human cytochromes P450. Curr. Opin. Drug Discov. Dev. 1999, 2(1), 15-19.
148. Shou, W. Z.; Magis, L.; Li, A. C.; Weng, N.; Bryant, M. S. A novel approach to perform metabolite screening during the quantitative LC-MS/MS analyses of in vitro metabolic stability samples using a hybrid triple-quadrupole linear ion trap mass spectrometer. J. Mass Spectrom. 2005, 40(10), 1347-1356.
149. Fonsi. M.; Orsale, M. V; Monteagudo, E. High-throughput microsomal stability assay for screening new chemical entities in drug discovery. Journal of biomolecular screening: the official j. Soc. Biomol. Screen. 2008, 13(9), 862-9.
150. Di, L.; Kerns, E. H.; Ma, X. J.; Huang, Y.; Carter, G. T. Applications of high throughput microsomal stability assay in drug discovery. Comb. Chem. High Throughput Screen. 2008, 11(6), 469-476.
151. Di, L.; Kerns, E. H.; Li, S. Q.; Petusky, S. L. High throughput microsomal stability assay for insoluble compounds. Int. J. Pharm. 2006, 317(1), 54-60.
152. Shou, M.; Dai, R. Analysis of in vitro cytochrome P450 inhibition in drug discovery and development. Drug Metab. Drug Des. Dev. 2008, 513-544.
153. Obach, R. Scott. Inhibition of drug-metabolizing enzymes and drug - drug interactions in drug discovery and development. Drug Drug Interac. Pharm. Dev. 2008, 75-93.
154. Smith, D.; Sadagopan, N.; Zientek, M.; Reddy, A.; Cohen, L. Analytical approaches to determine cytochrome P450 inhibitory potential of new chemical entities in drug discovery. J. Chromatogr. B. Anal. Technol. Biomed. Life Sci. 2007, 850(1-2), 455-463.
155. Di, Li; Kerns, E. H.; Li, S. Q.; Carter, G. T. Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS. Int. J. Pharm. 2007, 335(1-2), 1-11.
156. Peng, S. X; Barbone, A. G.; Ritchie, D. M. High-throughput cytochrome p450 inhibition assays by ultrafast gradient liquid chromatography with tandem mass spectrometry using monolithic columns. Rapid Commun. Mass Spectrom. RCM 2003, 17(6), 509-18.
157. Houston, J. B.; Kenworthy, K. E. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab. Dispos. 2000, 28(3), 246-254.
158. Emoto, C.; Yamazaki, H.; Iketaki, H.; Yamasaki, S.; Satoh, T.; Shimizu, R.; Suzuki, S.; Shimada, N.; Nakajima, M.; Yokoi, T. Cooperativity of ??-naphthoflavone in cytochrome P450 3A-dependent drug oxidation activities in hepatic and intestinal microsomes from mouse and human. Xenobiotica 2001, 31(5), 265-275.
159. Furuta, S.; Kamada, E.; Suzuki, T.; Sugimoto, T.; Kawabata, Y.; Shinozaki, Y.; Sano, H. Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica 2001, 31(1), 1-10.
160. McGinnity, D. F.; Waters, N. J.; Tucker, J.; Riley, R. J. Integrated in vitro analysis for the in vivo prediction of cytochrome P450 - mediated drug-drug interactions. Drug Metab. Dispos. 2008, 36(6) 1126-1134.
161. Lewis, D. F. V. Cytochromes P450, Taylor & Francis Inc., Bristol, PA, 1996.
162. Cui, X.; Thomas, A.; Gerlach, V.; White, R. E.; Morrison, R. A.; Cheng, K.-C. Application and interpretation of hPXR screening data: Validation of reporter signal requirements for prediction of clinically relevant CYP3A4 inducers. Biochem. Pharm. 2008, 76(5), 680-689.
163. Flaveny, C. A.; Murray, I. A.; Chiaro, C. R.; Perdew, G. H. Ligand selectivity and gene regulation by the human aryl hydrocarbon receptor in transgenic mice. Mol. Pharmacol. 2009, 75(6), 1412-20.
164. www.Puracyp.com
165. Hoke, S. H. II.; Tomlinson, J. A.; Bolden, R. D.; Morand, K. L.; Pinkston, J. D.; Wehmeyer, K. R. Increasing bioanalytical throughput using pcSFC-MS/MS: 10 minutes per 96-well plate. Anal. Chem. 2001, 73(13), 3083-3088.
166. Tong, X.; Wang, J.; Ita, I. E.; Zheng, S.; Pivnichny, J. V.; Griffin, P. High throughput in vivo pharmacokinetics studies and in vitro assays by using Beckman liquid handling system. Abstr. Pap. Am. Chem. Soc. 2001, 221, ANYL-077.
167. Gao, V. C. X.; Luo, W. C.; Ye, Q.; Thoolen, M. Column switching in high-performance liquid chromatography with tandem mass spectrometric detection for high-throughput preclinical pharmacokinetic studies. J. Chromatogr. A 1998, 828(1 + 2), 141-148.
168. Muck, W. Quantitative analysis of pharmacokinetic study samples by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). Pharmazie 1999, 54(9), 639-644.
169. Poon, G. K.; Kwei, G.; Wang, R.; Lyons, K.; Chen, Q.; Didolkar, V.; Hop, C. E. C. A. Integrating qualitative and quantitative liquid chromatography/ tandem mass spectrometric analysis to support drug discovery. Rapid Commun. Mass Spectrom. 1999, 13(19), 1943-1950.
170. Romanyshyn, L.; Tiller, P. R.; Hop, C. E. C. A. Bioanalytical applications of "fast chromatography" to high-throughput liquid chromatography/tandem mass spectrometric quantitation. Rapid Commun. Mass Spectrom. 2000, 14(18), 1662-1668.
171. Wu, J-T. The development of a staggered parallel separation liquid chromatography/tandem mass spectrometry system with on-line extraction for high-throughput screening of drug candidates in biological fluids. Rapid Commun. Mass Spectrom. 2001, 15(2), 73-81.
172. Korfmacher, W. Strategies and techniques for higher throughput ADME/ PK assays. High-Throughput Anal. Pharm. Ind. 2009, 205-231.
173. Musteata, F. M.; de Lannoy, I.; Gien, B.; Pawliszyn, J. Blood sampling without blood draws for in vivo pharmacokinetic studies in rats. J. Pharm. Biomed. Anal. 2008, 47(4-5), 907-912.
174. Xu, X. HPLC method development for drug discovery LC-MS assays in rapid pharmacokinetics applications. Separation Sci. Technology (San Diego, CA, United States) 2007, 8(HPLC Method Development for Pharmaceuticals), 317-351.
175. Bock, M. J.; Neilson, K. L.; Dudley, A. Use of trifluoroacetic acid to quantify small, polar compounds in rat plasma during discoveryphase pharmacokinetic evaluation. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2007, 856(1-2), 165-170.
176. White, R. E.; Manitpisitkul, P. Pharmacokinetic theory of cassette dosing in drug discovery screening. Drug Metab. Dispos. 2001, 29(7), 957-966.
177. Kuo, Be-S.; Van Noord, T.; Feng, M. R.; Wright, D. S. Sample pooling to expedite bioanalysis and pharmacokinetic research. J. Pharm. Biomed. Anal. 1998, 16(5), 837-846.
178. Wu, J.-T.; Zeng, H.; Qian, M.; Brogdon, B. L.; Unger, S. E. Direct plasma sample injection in multiple-component LC-MS-MS assays for high-throughput pharmacokinetic screening. Anal. Chem. 2000, 72(1), 61-67.
179. Johnson, D.E.; Wolfgang, G.H.I. Assessing the potential toxicity of new pharmaceuticals. Curr. Top. Med. Chem. (Hilversum, Netherlands) 2001, 1(4), 233-245.
180. Olson, H.; Betton, G.; Robinson, D.; Thomas, K.; Monro, A.; Kolaja, G.; Lilly, P.; Sanders, J.; Sipes, G.; Bracken, W.; Dorato, M.; Van Deun, K.; Smith, P.; Berger, B.; Heller, A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmmacol. 2000, 32(1), 56-67.
181. Kalgutkar, A.S.; Gardner, I.; Obach, R.S.; Shaffer, C.L.; Callegari, E.; Henne, K.R.; Mutlib, A.E.; Dalvie, D.K.; Lee, J.S.; Nakai, Y.; O'Donnell, J.P.; Boer, J.; Harriman, S.P. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab. 2005, 6, 161-225.
182. Argoti, D.; Liang, L.; Conteh, A.; Chen, L.; Bershas, D.; Yu, C-P.; Vouros, P.; Yang, E. Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LCMS/ MS). Chem. Res. Toxicol. 2005, 18(10), 1537-1544.
183. Dikalova, A.E.; Kadiiska, M.B.; Mason, R.P. An in vivo ESR spin-trapping study: free radical generation in rats from formate intoxication-role of the Fenton reaction. Proceedings of the Nat. Acad. Sci. USA 2001, 98(24), 13549-13553.
184. Pluim, D.; Maliepaard, M.; van Waardenburg, R.C.; Beijnen, J.H.; Schellens, J.H. 32P-postlabeling assay for the quantification of the major platinum-DNA adducts. Analyt. Biochem. 1999, 275, 30-38.
185. Terashima, I.; Suzuki, N.; Shibutani, S. 32P-Postlabeling/polyacrylamide gel electrophoresis analysis: application to the detection of DNA adducts. Chem. Res. Toxicol. 2002, 15, 305-311.
186. Shibutani, S.; Suzuki, N.; Laxmi, Y.R.S.; Schild, L.J.; Divi, R.L.; Grollman, A.P. Poirier M C: Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen. Cancer Res. 2003, 63(15) 4402-4406.
187. Maron, D.M.; Ames, B.N. Revised methods for the Salmonella mutagenicity test. Mutat. Res. 1983, 113, 173-215.
188. Fluckiger-Isler, S.; Baumeister, M.; Braun, K.; Gervais, V.; Nguyen-Hasler, N.; Reimann, R.; Van Gompel, J.; Wunderlich, HG.; Engelhardt, G. Assessment of the performance of the AmesII™ assay: a collaborative study with 19 coded compounds. Mutat. Res. 2004, 558(3) 181-197
189. Applegate, M.L.; Moore, M.M.; Broder, C.B.; Burrell, A.; Hozier, J.C. Molecular dissection of mutations at the heterozygous thymidine kinase locus in mouse lymphoma cells. Proc. Natl. Acad. Sci. 1990, 87, 51-55.
190. Miyamoto, Y.; Koh, Y.H.; Park, Y.S.; Fujiwara, N.; Sakiyama, H.; Misonou, Y.; Ookawara, T.; Suzuki, K.; Honke, K.; Taniguchi, N. Oxidative stress caused by inactivation of glutathione peroxidase and adaptive responses. Biol. Chem. 2003, 384(4) 567-574.
191. Lautraite, S.; Lasserre-Bigot, D.; Bars, R.; Carmichael, N. Optimization of cell-based assays for medium throughput screening of oxidative stress. In Vitro 2003, 17, 207-220.
192. Loetchutinat, C.; Kothan, S.; Dechsupa, S.; Meesungnoen, J.; Jay-Gerin, J-P.; Mankhetkorn, S. Spectrofluorometric determination of intracellular levels of reactive oxygen species in drug-sensitive and drug-resistant cancer cells using the 2′, 7′ -dichlorofluorescein diacetate assay. Radiat. Phys. Chem. 2004, 72(2-3), 323-331.
193. Schoonen, W.G.E.J.; de Roos, J.A.D.M.; Westerink, W.M.A.; Debiton, E. Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells. Toxicol. In Vitro 2005, 19(4), 491-503.
194. Dambach, D.M.; Andrews, B.A.; Moulin, F. New technologies and screening strategies for hepatotoxicity: Use of in vitro models. Toxicol. Pathol. 2005, 33,17-26.
195. York, J.L.; Maddox, L.C.; Zimniak, P.; McHugh, T.E.; Grant, D.F. Reduction of MTT by glutathione S-transferase. BioTechniques 1998, 25(4), 626-628.
196. Riss, T.L.; Moravec, R.A. Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays. Assay Drug Dev. Technol. 2004, 2(1), 51-62.
197. Higgins, J. D. Perspectives on preformulation programs at the discovery -development inferface. Am. Pharm. Rev. 2009, 12(3), 42-46.
198. Merisko-Liversidge, E. M.; Liversidge, G. G. Drug nanoparticles: formulating poorly water-soluble compounds. Toxicol. Pathol. 2008, 36(1), 43-48.
199. Huang, L-f.; Dong, J. Formulation strategies and practice used for drug candidates with water-insoluble properties for toxicology, biology, and pharmacology studies in discovery support. Water-Insoluble Drug Formul. 2nd ed., 2008, 113-132.
200. Wahlstrom, J. L.; Chiang, P-C.; Ghosh, S.; Warren, C. J.; Wene, S. P.; Albin, L. A.; Smith, M. E.; Roberds, S. L. Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment. Nanoscale Res. Lett. 2007, 2(6) 291-296.
201. Li, P.; Zhao, L. Developing early formulations: Practice and perspective. Int. J. Pharm. 2007, 341(1-2), 1-19.
202. Bittner, B.; Mountfield, R J. Formulations and related activities for the oral administration of poorly water-soluble compounds in early discovery animal studies: an overview of frequently applied approaches: part 2. Pharm. Ind. 2002, 64(9), 985-991.
203. Bittner, B.; Mountfield, R. J. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr. Opin. Drug Discov. Dev. 2002, 5(1) 59-71.
204. Fessey, R. E.; Austin, R. P.; Barton, P.; Davis, A. M.; Wenlock, M. C. The role of plasma protein binding in drug discovery. Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, [LogP2004, Lipophilicity Symposium], 3rd, Zurich, Switzerland, Feb. 29-Mar. 4, 2004 (2006), 119-141.
205. Cohen, L. H. Plasma protein-binding methods in drug discovery. Optim. Drug Discov. 2004, 111-122.
206. Crick, E. W.; Osorio, I.; Bhavaraju, N. C.; Linz, T. H.; Lunte, C. E. An investigation into the pharmacokinetics of 3-mercaptopropionic acid and development of a steady-state chemical seizure model using in vivo microdialysis and electrophysiological monitoring. Epilepsy Res. 2007, 74(2-3), 116-125.
207. Salphati, L.; Childers, K.; Pan, L.; Tsutsui, K.; Takahashi, L. Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man. J. Pharm. Pharmacol. 2001, 53(7), 1007-1013
208. Letendre, L.; Scott, M.; Dobson, G.; Hidalgo, I.; Aungst, B. Evaluating barriers to bioavailability in vivo: Validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. Pharm. Res. 2004, 21(8), 1457-1462.
209. Chen, Y.; Monshouwer, M.; Fitch, W. L. Analytical tools and approaches for metabolite identification in early drug discovery. Pharm. Res. 2007, 4(2), 248-257.
210. Baranczewski, P.; Stanczak, A.; Kautiainen, A.; Sandin, P.; Edlund, P.-O. Introduction to early in vitro identification of metabolites of new chemical entities in drug discovery and development. Pharmacol. Rep. 2006, 58(3), 341-352.
211. Beattie, I.; Joncour, K.; Lawson, K. Ultra performance liquid chromatography coupled to orthogonal quadrupole TOF-MS(MS) for metabolite identification. LC-GC Europe 2005, 19-21, 24-27.
212. Mager, D. E.; Woo, S.; Jusko, W. J. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab. Pharm. 2009, 24(1), 16-24.
213. Riss, T.L.; Moravec, R.A. Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays. Assay Drug Develop. Technol. 2004, 2(1), 51-62.
214. Mikus, J.; Steverding, D. A simple colorimetric method to screen drug cytotoxicity against Leishmania [by] using the dye Alamar Blue. Parasitol. Int. 2000, 48(3), 265-269.
215. McMillian, M.K.; Grant, E.R.; Zhong, Z.; Parker, J.B.; Li, L.; Zivin, R.A.; Burczynski, M.E.; Johnson, D. Nile Red binding to HepG2 cells: an improved assay for in vitro studies of hepatosteatosis. In Vitro Mol. Toxicol. 2001, 14(3), 177-190.
216. Xu, J.J.; Diaz, D.; O'Brien, P.J. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem-Biol. Interact. 2004, 150(1) 115-128.
217. Samuel, K.; Yin, W.; Stearns, R.A.; Tang, Y.S.; Chaudhary, A.G.; Jewell, J.P.; Lanza, Jr L.; Lin, L.S.; Hagmann, W.K.; Evans, D. C.; Kumar, S. Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques. J. Mass Spectrom. 2003, 38, 211-221.
218. Gralinski, M. R.: The assessment of potential for QT interval prolongation with new pharmaceuticals. Impact Drug Dev. J. Pharmacol. Toxicol. Methods 2000, 43(2), 91-99
219. January, C. T.; Gong, Q.; Zhou, Z. Defective protein trafficking of HERG K+ channels in human congenital long QT syndrome. Pharm. News 2000, 7(4), 27-34
220. Abrahamsson, C. Neuropeptide Y1- and Y2-receptor-mediated cardiovascular effects in the anesthetized guinea pig, rat, and rabbit. J. Cardiovasc. Pharmacol. 2000, 36(4), 451-458
221. Pourrias, B.; Porsolt, R. D.; Lacroix, P. QT interval prolongation by noncardiovascular drugs: a proposed assessment strategy. Drug Dev. Res. 1999, 47, 55-62
222. Fermini, B.; Fossa, A.A. Preclinical assessment of drug-induced QT interval prolongation. Current issues and impact on drug discovery. Ann. Rep. Med. Chem. 2004, 39,323-334.
223. Guo L, Guthrie H: Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J. Pharmacol. Toxicol. Methods 2005, 52(1), 123-135.
224. Hammond, T.G.; Pollard, C.E. Use of in vitro methods to predict QT prolongation. Toxicol. Appl. Pharmacol. 2005, 207(Suppl): 446-450.
225. Finlayson, K.; Witchel, H.J.; McCulloch, J.; Sharkey, J. Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur. J. Pharmacol. 2004, 500(1-3), 129-142.
226. Abbott, N. J.; Dolman, D. E. M.; Patabendige, A. K.: Assays to predict drug permeation across the blood - brain barrier, and distribution to brain. Curr. Drug Metab. 2008, 9(9), 901-910.
227. Kortagere, S.; Chekmarev, D.; Welsh, W. J.; Ekins, S. New predictive models for blood - brain barrierpPermeability of drug - like molecules. Pharm. Res. 2008, 25(8), 1836-1845.
228. Blokland, A.; Hinz, V.; Schmidt, B.H. Effects of metrifonate and tacrine in the spatial Morris task and modified Irwin Test: evaluation of the efficacy/safety profile in rats. Drug Dev. Res. 1995, 36(4) 166-179.
229. Alarcon-Corredor, O. M.; Alfonso, R. Clinical and biochemical alterations in rats treated with high doses of vitamin A. Arch. Latinoamericanos de Nut. 2007, 57(3), 224-230.
230. Bandyopadhyay, S.; Varshney, J. P.; Hoque, M.; Ghosh, M. K.: Clinical, serum bio-chemical and enzymatic features of dogs with cholecystic disorders. Indian Vet. J. 2008, 85(4), 368-370.
231. Schuurman, H-J.; Smith H. T. Reference values for clinical chemistry and clinical hematology parameters in cynomolgus monkeys. Xenotransplantation 2005, 12(1), 72-5.